David W. Ayer

533 total citations
18 papers, 349 citations indexed

About

David W. Ayer is a scholar working on Psychiatry and Mental health, Clinical Psychology and Pathology and Forensic Medicine. According to data from OpenAlex, David W. Ayer has authored 18 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 5 papers in Clinical Psychology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in David W. Ayer's work include Migraine and Headache Studies (12 papers), Psychosomatic Disorders and Their Treatments (7 papers) and Trigeminal Neuralgia and Treatments (3 papers). David W. Ayer is often cited by papers focused on Migraine and Headache Studies (12 papers), Psychosomatic Disorders and Their Treatments (7 papers) and Trigeminal Neuralgia and Treatments (3 papers). David W. Ayer collaborates with scholars based in United States, Canada and Japan. David W. Ayer's co-authors include Janet H. Ford, Eric D. Achtyes, Donald Goff, David Schoenfeld, A. Eden Evins, Gladys N. Pachas, Susanne S. Hoeppner, Corinne Cather, Richard B. Lipton and Rebecca M. Speck and has published in prestigious journals such as JAMA, Neurology and Psychiatry Research.

In The Last Decade

David W. Ayer

18 papers receiving 335 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David W. Ayer United States 9 173 149 88 66 43 18 349
Gail F. Kirk United States 5 226 1.3× 29 0.2× 115 1.3× 105 1.6× 43 1.0× 5 633
Simone Bolognesi Italy 12 98 0.6× 37 0.2× 24 0.3× 136 2.1× 40 0.9× 34 380
Lluïsa Ortega Spain 12 81 0.5× 27 0.2× 181 2.1× 76 1.2× 11 0.3× 35 466
Howard R. Steinberg United States 10 53 0.3× 162 1.1× 27 0.3× 217 3.3× 36 0.8× 12 500
Alexandra P. Metse Australia 13 29 0.2× 102 0.7× 40 0.5× 19 0.3× 23 0.5× 38 351
Hannah Bowers United Kingdom 8 203 1.2× 44 0.3× 54 0.6× 58 0.9× 4 0.1× 16 330
Rachel Horne United States 6 75 0.4× 21 0.1× 51 0.6× 171 2.6× 14 0.3× 8 367
Kürşat Altınbaş Türkiye 10 166 1.0× 39 0.3× 11 0.1× 121 1.8× 15 0.3× 61 372
Atila Erol Türkiye 14 102 0.6× 29 0.2× 24 0.3× 147 2.2× 13 0.3× 35 345
Sarah Overton United Kingdom 8 80 0.5× 36 0.2× 18 0.2× 49 0.7× 9 0.2× 14 367

Countries citing papers authored by David W. Ayer

Since Specialization
Citations

This map shows the geographic impact of David W. Ayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. Ayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. Ayer more than expected).

Fields of papers citing papers by David W. Ayer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David W. Ayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. Ayer. The network helps show where David W. Ayer may publish in the future.

Co-authorship network of co-authors of David W. Ayer

This figure shows the co-authorship network connecting the top 25 collaborators of David W. Ayer. A scholar is included among the top collaborators of David W. Ayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David W. Ayer. David W. Ayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Ford, Janet H., Wenyu Ye, David W. Ayer, et al.. (2023). Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine. Journal of Patient-Reported Outcomes. 7(1). 34–34. 6 indexed citations
2.
Ashina, Messoud, Caroline Roos, Mika Komori, et al.. (2023). Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial. Cephalalgia. 43(4). 2215206801–2215206801. 4 indexed citations
3.
4.
Speck, Rebecca M., et al.. (2020). A Qualitative Study to Assess the Content Validity of the 24‐Hour Migraine Quality of Life Questionnaire in Patients with Migraine. Headache The Journal of Head and Face Pain. 60(9). 1982–1994. 4 indexed citations
5.
Ford, Janet H., Virginia L. Stauffer, Peter McAllister, et al.. (2020). Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study. Quality of Life Research. 30(2). 455–464. 6 indexed citations
6.
Ford, Janet H., Cristina Tassorelli, Élizabeth Leroux, et al.. (2020). Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). Quality of Life Research. 30(1). 105–115. 17 indexed citations
7.
Ford, Janet H., Tobias Kurth, Amaal J. Starling, et al.. (2020). Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine. Headache The Journal of Head and Face Pain. 60(10). 2304–2319. 8 indexed citations
8.
Speck, Rebecca M., Kathleen W. Wyrwich, Ren Yu, et al.. (2019). Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality‐of‐Life Questionnaire Version 2.1 Electronic Patient‐Reported Outcome in Patients With Episodic and Chronic Migraine. Headache The Journal of Head and Face Pain. 59(5). 756–774. 19 indexed citations
9.
Speck, Rebecca M., et al.. (2019). Content validity of the Migraine-Specific Quality of Life Questionnaire version 2.1 electronic patient-reported outcome. Journal of Patient-Reported Outcomes. 3(1). 39–39. 12 indexed citations
10.
Ford, Janet H., David W. Ayer, Qi Zhang, et al.. (2019). Two randomized migraine studies of galcanezumab. Neurology. 93(5). e508–e517. 25 indexed citations
11.
Gable, Julia, David W. Ayer, Allicia C. Girvan, et al.. (2018). PCN366 - QUALITATIVE PATIENT INTERVIEWS TO SUPPORT THE FACT HEPATOBILIARY SYMPTOM INDEX-8 AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN. Value in Health. 21. S76–S76. 1 indexed citations
12.
Ayer, David W., Vladimir Skljarevski, Janet H. Ford, et al.. (2018). Measures of Functioning in Patients With Episodic Migraine: Findings From a Double‐Blind, Randomized, Placebo‐Controlled Phase 2b Trial With Galcanezumab. Headache The Journal of Head and Face Pain. 58(8). 1225–1235. 25 indexed citations
13.
Ford, Janet H., David W. Ayer, Allen W. Nyhuis, Sheena K. Aurora, & Jeff Carter. (2017). Measures of functioning using MSQ v2.1 in patients with a history of episodic migraine and treated with galcanezumab or placebo injections in a Phase 2 clinical trial (P2.179). Neurology. 88(16_supplement). 2 indexed citations
14.
Lewis, Cara C., C. Nathan Marti, Brigid R. Marriott, Kelli Scott, & David W. Ayer. (2017). Patterns of practice in community mental health treatment of adult depression. Psychotherapy Research. 29(1). 70–77. 5 indexed citations
15.
Brodey, Benjamin B., et al.. (2015). Validation of the NetSCID: an automated web-based adaptive version of the SCID. Comprehensive Psychiatry. 66. 67–70. 29 indexed citations
16.
Evins, A. Eden, Corinne Cather, Gladys N. Pachas, et al.. (2014). Maintenance Treatment With Varenicline for Smoking Cessation in Patients With Schizophrenia and Bipolar Disorder. JAMA. 311(2). 145–145. 152 indexed citations
17.
Shaw, Terry V., et al.. (2013). Child Welfare Birth Match: Timely Use of Child Welfare Administrative Data to Protect Newborns. Journal of Public Child Welfare. 7(2). 217–234. 7 indexed citations
18.
Ayer, David W., Karu Jayathilake, & Herbert Y. Meltzer. (2008). The InterSePT suicide scale for prediction of imminent suicidal behaviors. Psychiatry Research. 161(1). 87–96. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gail F. Kirk Breakdown of academic impact, for papers by Simone Bolognesi Breakdown of academic impact, for papers by Lluïsa Ortega Breakdown of academic impact, for papers by Howard R. Steinberg Breakdown of academic impact, for papers by Alexandra P. Metse Breakdown of academic impact, for papers by Hannah Bowers Breakdown of academic impact, for papers by Rachel Horne Breakdown of academic impact, for papers by Kürşat Altınbaş Breakdown of academic impact, for papers by Atila Erol Breakdown of academic impact, for papers by Sarah Overton
Rankless by CCL
2026